The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

Bristol Myers Squibb could quickly realize a return on its investment thanks to a KarXT launch that is widely expected to begin before the end of 2024. The FDA is reviewing an application that ...

Bristol-Myers Squibb has new data backing up the value of mavacamten for obstructive hypertrophic cardiomyopathy (HCM), as it waits for a delayed verdict on its marketing application for the drug ...

Clinicians are at the sharp end of the mismatch between resources and demand. As a researcher Lillian Siu, an oncologist at Toronto’s Princess Margaret Cancer Centre, is striving to break new ground ...

The CTLA4 inhibitor – now given the brand name Imjudo – is only the second drug in the class to be approved after Bristol-Myers Squibb's well ... review time for the application to six months.

Existing investors Bristol-Myers Squibb, Byers Capital, Hitachi Ventures ... of our T-cell engineering approach and have given us the confidence to broaden the application of our technology to address ...

Although the data from RCTs may not directly translate to the ‘real world’,7 whatever generalisability is lost due to the application of strict inclusion ... Boehringer-Ingelheim, Bristol-Myers Squibb ...

BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target ...

Bristol Myers Squibb Co. closed $10.05 below its 52-week high ($59.46), which the company reached on September 22nd.

In the assessment of 12-month price targets, analysts unveil insights for Bristol-Myers Squibb, presenting an average target ...

Bristol Myers Squibb (BMY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.